In breast cancer models, CAF–specific SHCBP1 knockout enhanced the antitumor activity of Erdafitinib and PD-1 blockade, largely by influencing immune cell recruitment and inhibiting CAF activity [24]. Here, SHCBP1 is linked to breast cancer.